DPP-4inhibitors (insulin-based therapy), a new class of hypoglycemic agents for clinical practice, their role in diabetic nephropathy, with a particular focus on renal protection and alternative markers of cardiovascular disease (91). Here, INS is linked to diabetic kidney disease.